FOR IMMEDIATE RELEASE
January 24, 2002
Burlington, Ontario

THE JENEX CORPORATION ("Jenex" or the "Corporation") (CDNX - JEN), is pleased to announce the addition of Mr. Gilbert Smith to its Corporate Advisory Committee. Mr. Smith brings valuable corporate and entrepreneurial experience and a history of professional accomplishments. Mr. Smith becomes the 5th member of the Corporation's Accomplished Advisory Committee (see www.jenexcorp.com). The Advisory Committee is an integral part of the Corporation's strategy to seek experienced professional advisors to assist the Company in achieving its corporate goals.

Mr. Smith joined Helene Curtis in 1976 as Vice President of sales and served with the company until 1998. During that time he was a member of the Board of Directors, Executive Vice President and Chief Operating Officer. President of Helene Curtis North America, and for 13 years he was President of the U. S. Consumer Division. Prior to that assignment he was both Vice President of Sales and Marketing. With the acquisition of Helene Curtis by Unilever, Mr. Smith was appointed Executive Vice President and Chief Operating Officer of Helene Curtis, and Senior Vice President of Unilever North America. In this role he led both Helene Curtis and the customer management integration of Lever Brothers, Chesebrough Ponds, and Helene Curtis. Prior to joining Helene Curtis, Mr. Smith was in sales and sales management with Procter & Gamble and Carter Products. Mr. Smith attended the Advanced Management Program at the Harvard Business School, and graduated with a degree in Economics from Florida State University. Mr. Smith is currently owner, and Vice Chairman of, a start-up household cleaning products company.

About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation has developed and patented a thermal therapeutic device for the prevention of cold sores. Patents in fifteen countries, including the United States, Canada, Australia, and the E.E.C protect the technology. A license to market from regulatory, Therapeutic Products Programme (TPP), in Canada has been received to market their thermal therapy device, over-the-counter (OTC) with the claim "For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks". A medical device number has been issued by TPP, in accordance with Medical Device Regulations. Jenex is the first company to receive clearance to market from a significant regulatory body to make the prevention claim for cold sores.

The Corporation is currently seeking clearance from FDA to make a similar marketing claim in the United States. Management of the Corporation expects a response from the FDA in the 2nd quarter of 2002. Regulatory approvals are being pursued in all European countries and Australia.

Jenex is now seeking a strategic corporate partner to license and commercialize their thermal therapy technology. Several Multi-National Companies have signed Confidentiality Agreements and are in various stages of due diligence.

The HSV-1 virus that causes cold sores, is endemic in North America, and is estimated to affect 80% of the population. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation's thermal therapy product has the potential to dominate a large and underdeveloped market.

"Prevention is the Solution"

For further information, see www.jenexcorp.com or contact:

Michael A. Jenkins, President
The Jenex Corporation
207 - 940 Sheldon Court
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: Jenex@sprint.ca

The Canadian Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.